Indeno[2,1-b]pyrrole | 246-96-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: Indeno[2,1-b]pyrrole
• CAS: 246-96-8
• 化学式: C₁₁H₇N
• mdl: MFCD18449555
• 分子量: 153.18
• InChiKey: CNAFOLPGHNAMBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
  申请人：Bennani L. Youssef

  公开号：US20060025601A1

  公开（公告）日：2006-02-02

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明一般涉及一系列化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为治疗剂的使用。更具体地，本发明的化合物是三环茚并吡咯化合物。这些化合物是血清素受体（5-HT）的配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、障碍和状况（例如焦虑、抑郁和肥胖）。
• Benzo-isoquinoline derivatives and analogs and their use in therapeutics
  申请人：THE UPJOHN COMPANY

  公开号：EP0539209A1

  公开（公告）日：1993-04-28

  The present invention encompasses: 1) compounds of formula I below, wherein p and s are independent and may be either 1 or 2, wherein R₁ is -H, -Halo, -CN, -CO₂H, -CO₂R₁₋₁, -CONH₂, -CONHR₁₋₁, -CON(R₁₋₁)₂, -SH,- SR₁₋₁, -SO₂R₁₋₁, SO₂NH₂, -SO₂NHR₁₋₁, -SO₂N(R₁₋₁)₂, -OR₁₋₁, -OSO₂CF₃, -OSO₂R₁₋₁, -NH₂, -NHR₁₋₁, or -N(R₁₋₁)₂; wherein R₁₋₁ is -H, -(C₁-C₈ alkyl), -(C₁-C₈ alkenyl), -(C₃-C₁₀ cycloalkyl), -(C₆ aryl), -5 or 6 member heterocyclics, -(C₁-C₈ alkyl)-(5 or 6 member heterocyclics), wherein R₂ is -H, -Halo, -CN, -CF₃, -SH, or -SR₂₋₁; wherein R₂₋₁ = R₁₋₁, wherein R₃ is -H, -(C₁-C₈ alkyl), -(C₁-C₈ alkenyl), -(C₆ aryl), -(C₃-C₁₀ cycloalkyl), -(5 or 6 member heterocyclics), -(C₁-C₈ alkyl)-5 or 6 member heterocyclics), wherein R₃₋₁ = R₁₋₁ or a pharmacologically acceptable salt thereof. 2. A pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and an effective amount of a compound of formula I. 3. A method of treating central nervous system disorders, associated with serotonin and or dopamine receptor activity comprising: administering an effective amount of a compound of formula I to a patient in need thereof. The compounds of this invention possess selective pharmacological properties and are useful in treating central nervous system disorders.

  本发明涵盖以下内容：1）以下式I的化合物，其中p和s是独立的，可以是1或2，其中R₁是-H，-Halo，-CN，-CO₂H，-CO₂R₁₋₁，-CONH₂，-CONHR₁₋₁，-CON（R₁₋₁）₂，-SH，-SR₁₋₁，-SO₂R₁₋₁，SO₂NH₂，-SO₂NHR₁₋₁，-SO₂N（R₁₋₁）₂，-OR₁₋₁，-OSO₂CF₃，-OSO₂R₁₋₁，-NH₂，-NHR₁₋₁或-N（R₁₋₁）₂;其中R₁₋₁是-H，-（C₁-C₈烷基），-（C₁-C₈烯基），-（C₃-C₁₀环烷基），-（C₆芳基），-5或6成员杂环，-（C₁-C₈烷基）-（5或6成员杂环），其中R₂是-H，-Halo，-CN，-CF₃，-SH或-SR₂₋₁;其中R₂₋₁ = R₁₋₁，其中R₃是-H，-（C₁-C₈烷基），-（C₁-C₈烯基），-（C₆芳基），-（C₃-C₁₀环烷基），-（5或6成员杂环），-（C₁-C₈烷基）-5或6成员杂环），其中R₃₋₁ = R₁₋₁或其药理学上可接受的盐。2.由药学上可接受的载体和式I化合物的有效量组成的药物组合物。3.一种治疗与血清素和/或多巴胺受体活性相关的中枢神经系统疾病的方法，包括向需要该化合物的患者施用式I化合物的有效量。本发明的化合物具有选择性药理特性，并可用于治疗中枢神经系统疾病。
• TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS
  申请人：Bennani Youssef L.

  公开号：US20090239925A1

  公开（公告）日：2009-09-24

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明通常涉及一系列化合物，包括含有这些化合物的药物组合物，以及将这些化合物和组合物用作治疗剂。更具体地说，本发明的化合物是三环吲哚-吡咯化合物。这些化合物是血清素受体（5-HT）配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、障碍和病状（例如焦虑、抑郁和肥胖症）。
• Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators
  申请人：Bennani Youssef L.

  公开号：US20110172283A1

  公开（公告）日：2011-07-14

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

  本发明通常涉及一系列化合物，含有这些化合物的制药组合物，以及将这些化合物和组合物用作治疗剂的用途。更具体地说，本发明的化合物是三环吲哚-吡咯化合物。这些化合物是血清素受体（5-HT）配体，可用于治疗需要调节血清素受体（5-HT）活性的疾病、疾病和病情（例如焦虑、抑郁和肥胖症）。
• INDANO PYRROLIDINE CARBAMATES
  申请人：PFIZER INC.

  公开号：EP0538314B1

  公开（公告）日：1997-06-18